Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient’s future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine and published in the Journal of the American College of Cardiology (JACC). The team used imaging tests to detect disease in carotid or coronary arteries before it caused symptoms to better identify healthy individuals at increased risk than current, traditional risk assessment methods.
In the current study patients were assessed using traditional cardiovascular disease risk factor assessments for high blood pressure, abnormal cholesterol, diabetes, sedentary lifestyle, obesity, and smoking, and then additionally received two imaging tests. The tests were novel 3D vascular ultrasound and coronary artery calcium score via a low-dose computed tomography scan, respectively. Adding the two imaging tests resulted in the identification of subclinical atherosclerosis in 60 percent of the seemingly healthy study participants presenting with no clinical manifestations.
The current BioImage Study was launched to identify new ways to identify subclinical cardiovascular disease before symptoms arise to help curb the growing public health and economic concern of cardiovascular disease. For three years the project followed nearly 6,000 healthy men (ages 55 to 80 years) and women (60 to 88 years) with no history or symptoms of cardiovascular disease.
Novel 3D vascular ultrasound imaging technology allowed the researchers to quantify the amount of carotid artery plaque burden lining each patient’s carotid arteries in their neck, while a coronary artery calcium score CT scan allowed for the identification of any narrowing or hardening of the coronary arteries due to the buildup of fatty cholesterol and calcified plaque. Having increased prevalence of carotid plaque burden or coronary artery calcium are signs of atherosclerosis or diseased arteries. Only these imaging procedures could reveal this information in the healthy study participants.
The findings showed those apparently healthy individuals identified with increased carotid plaque burden and coronary artery calcium were two to three times more likely to have an adverse event such as an artery blockage, or a piece of plaque becoming loose causing a heart attack or stroke. In fact, after follow-up (2.5 to 3.1 years), there were a total of 216 adverse events reported among study participants including 108 deaths, of which 27 were cardiovascular, plus 34 heart attacks, 30 strokes, 18 experienced unstable angina and hospitalized, and 79 needed revascularization procedures.
Over the study duration the incidence of adverse events among those with the greatest amount of carotid and coronary atherosclerosis was 4.2 percent, approximately 8-fold higher compared to individuals with minimal disease in either vascular territory.
The team state that the study shows the significant impact of adding carotid plaque measurement using vascular ultrasound and coronary calcium scoring with CT scan to the conventional assessment for cardiovascular disease. Healthy patients with elevated calcium and plaque burden are at increased risk of experiencing adverse cardiovascular events in even a short period of just three years adding that assessing a patient’s risk of atherosclerosis with bioimaging yields incremental gains over classical risk factors in cardiovascular risk prediction.
The researcher surmise that the study shows simply adding one of the available cardiac bioimaging resources may more accurately predict a patient’s risk or diagnose their disease, also giving the medical community an opportunity to prevent them from experiencing a future cardiac event and possibly save more lives from the burdens of cardiovascular diseases. For patients’ lives and for the health of global economies the medical community need to improve predictive measures for cardiovascular disease and can no longer just rely on traditional risk factors.
According to researchers, their future research will analyze the cost-effectiveness of a new strategy of incorporating these non-invasive imaging tools into future prevention and diagnostic protocols for cardiovascular disease and to better define their use.
Source: The Mount Sinai Hospital
atherosclerosis, BioImage, biomarker, cardiac, cardiology, cardiovascular disease, coronary calcium scoring with CT scan, healthinnovations, heart attack, imaging, premature death, risk assessment, stroke, vascular ultrasound
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.